AI-assisted international press reviewPress review

ACS Group Partners with UPM to Enhance AI and Innovation Talent

ACS Group and UPM: A partnership to accelerate the training of tomorrow's leaders in AI and emerging technologies. From nuclear energy to data centers, and including semiconductors and sustainable mobility, this innovative collaboration integrates theory, practice, and innovation to tackle global industry challenges. Towards a future where talent and technology transform the world.

Source: Grupoacs, published under the title "ACS Group Promotes Talent Development in Partnership with UP..." - 20 November 2025

Turner Named America's Dream Employer by Forbes in 2026

Turner Construction: Recognized by Forbes as one of the Ideal Employers for the first two years of the ranking, thanks to an inclusive, innovative culture focused on well-being. This distinction highlights the company's commitment to providing inspiring opportunities, such as building hospitals that heal, data centers that fuel innovation, and stadiums that unite communities. With engaging career programs, cutting-edge AI tools, and an environment where every employee can thrive, Turner embodies professional excellence. Rosemarie Demonte, Chief Human Resources Officer, states: "This recognition reflects our culture of respect and opportunities for all." Explore careers at https://www.turnerconstruction.com/careers. A company where building and making a difference becomes reality.

Source: Hochtief, published under the title "Turner Named One of America’s Dream Employers for 2026 by Fo..." - 20 November 2025

PepsiCo Increases Dividend by 5%: 53rd Annual Rise

PepsiCo strengthens its sustainable commitment: A 5% dividend increase to support agri-food innovation. With its pep+ strategy, the company accelerates eco-friendly practices and positive agriculture while maintaining its global leadership in healthy beverages and foods. Since 1965, PepsiCo has multiplied annual dividends, marking 53 years of green and responsible growth. Discover how this evolution inspires a sustainable future for the industry.

Source: Pepsico, published under the title "PepsiCo declares quarterly dividend" - 20 November 2025

Novartis Targets 5-6% Annual Growth Through 2030 with Flourishing Pipeline

Novartis strengthens its outlook: Sales growth projected at 5-6% CAGR through 2030, with upward revisions for Kisqali and Scemblix. Eight key assets aim for $3-10 billion, supported by over 15 clinical advancements and a pipeline of more than 30 innovative drugs. An acquisition strategy for a sustainable future beyond 2030.

Source: Novartis, published under the title "Novartis projects +5-6% cc sales CAGR 2025-2030, with long-t..." - 20 November 2025

GSK Sues AnaptysBio Over Jemperli in Oncology

TESARO, a GSK subsidiary, is suing AnaptysBio for breaching an agreement regarding Jemperli (dostarlimab), an innovative treatment for endometrial cancers. GSK seeks contract termination, a perpetual license, and a 50% reduction in royalties. With Jemperli approved in over 35 countries and an ambitious clinical program for other cancers, this case could redefine the future of oncology. GSK reaffirms its commitment to fighting diseases despite the inherent risks of future projections. A crucial battle for biopharma innovation.

Source: Gsk, published under the title "TESARO, a GSK subsidiary, initiates litigation against Anapt..." - 20 November 2025

Merck Launches Eco-Efficient Supercomputer to Boost Research

Merck and Lenovo join forces with Equinix to launch an eco-efficient supercomputer in Munich, integrating Neptune® liquid cooling technology. This hybrid infrastructure, AI-ready, accelerates innovation in Life Sciences, Healthcare, and Electronics, while reinforcing Merck's commitment to energy efficiency and sustainable practices in high-performance computing.

Source: Merck, published under the title "Merck Launches High-Performance Computer to Accelerate Resea..." - 20 November 2025

Abbott Acquires Exact Sciences to Revolutionize Cancer Screening

Abbott acquires Exact Sciences for $21 billion: a revolution in early cancer detection. This strategic merger propels Abbott to the forefront of oncology diagnostics in the U.S., gaining access to innovations like Cologuard® and Oncotype DX®. Targeting a $60 billion market, it accelerates early detection, optimizes treatments, and boosts revenue growth. An investor conference is scheduled for today at 9 AM ET. Towards a transformed era of cancer care!

Source: Abbott, published under the title "Abbott To Acquire Exact Sciences, A Leader In Large And Fast..." - 19 November 2025

FDA Approves Bayer's HYRNUO for HER2-Mutant Lung Cancer

FDA approves sevabertinib for HER2-mutant NSCLC: an objective response rate of 71% in patients not previously treated with targeted therapy, according to the SOHO-01 trial. This innovative oral treatment offers durable anti-tumor responses and a manageable safety profile, addressing a cancer with poor prognosis and limited options. A major advance in targeted oncology.

Source: Bayer, published under the title "U.S. FDA grants accelerated approval to Bayer’s HYRNUO™ (sev..." - 19 November 2025

Koselugo Approved in the USA for NF1 in Adults

Major advancement in the treatment of neurofibromatosis type 1: Koselugo, the first oral MEK inhibitor from Alexion, has received FDA approval for adults with symptomatic, inoperable plexiform neurofibromas. Based on the Phase III KOMET trial, it shows an overall response rate of 20% in tumor size reduction, compared to 5% for placebo, with prolonged response duration in most patients. This therapy, already used in children, enhances options for ongoing management of this rare genetic disease, highlighting significant clinical progress supported by global experts.

Source: Astrazeneca, published under the title "Koselugo approved in the US for adults with neurofibromatosi..." - 19 November 2025

$European Commission Approves Roche's Lunsumio SC for Refractory Lymphoma$

European Commission Approves Roche's Lunsumio SC for Refractory Lymphoma

Lunsumio subcutaneous: A major breakthrough for relapsed follicular lymphoma, featuring high rates of durable and deep responses in third-line treatment and beyond. This innovative option simplifies administration to a single one-minute injection, providing optimal flexibility to meet clinical demands and patient lifestyle preferences. A Roche solution that transforms the therapeutic experience.

Source: Roche, published under the title "European Commission approves Roche’s Lunsumio subcutaneous f..." - 19 November 2025

VINCI: Record Traffic on Highways and Airports in 2025

Discover the latest innovations in plant technologies and agritech that are revolutionizing sustainable agriculture! Download our exclusive press release PDF now to explore advanced solutions against climate change, optimize yields, and promote eco-friendly food production. Don't miss this essential resource for industry professionals. Share your insights!

Source: Vinci, published under the title "VINCI Autoroutes and VINCI Airports traffic in October 2025" - 19 November 2025

Innovative Rehabilitation of the Warringah Freeway: A Concrete Award for Design Excellence

Award-winning Road Innovation: The upgrade of the Warringah Freeway wins the prestigious Arvo Tinni Award for its exceptional urban paving design. This project combines the legacy of the 1960s with modern techniques, such as new concrete profiles and environmental assessments, while managing intense traffic of 250,000 vehicles per day, demonstrating a commitment to sustainability and infrastructural performance.

Source: Cimic, published under the title "Warringah Freeway Upgrade wins major concrete paving award" - 19 November 2025

Opening of the New South Access Ramp of the Warringah Freeway in Sydney

The Warringah Freeway Upgrade marks a significant advancement with the opening of the new southbound Falcon Street ramp, effective November 8. This 101-meter bridge, featuring six steel beams weighing up to 80 tons, provides a dedicated bus lane at Neutral Bay, enhancing traffic flow and safety by separating traffic streams. Incorporating feedback from residents through a glare screen, the project, led by CPB Contractors and DT Infrastructure, will continue until 2026 to transform a key corridor in Sydney. Traffic changes, such as mandatory access via the new ramp for the harbor bridge, are now in effect. An innovative infrastructure serving daily mobility.

Source: Cimic - 19 November 2025

PepsiCo Mobilizes $225,000 for Hurricane Melissa Victims

PepsiCo and the PepsiCo Foundation take action after Hurricane Melissa: a substantial support of $225,000 for food security and hydration, through partnerships with World Central Kitchen. These efforts enhance access to essential resources, promoting sustainable community resilience and aligning with agritech innovations for a more stable food future. The Foundation, focused on food security and water, collaborates with global experts for tangible impacts. Media contact: Rachel.Kent@pepsico.com.

Source: Pepsico, published under the title "PepsiCo, PepsiCo Foundation and Pepsi-Cola Jamaica respond t..." - 19 November 2025

Roche's Giredestrant: A Breakthrough Against Early Breast Cancer

Giredestrant revolutionizes breast cancer treatment: Results from the lidERA trial show significant and clinically meaningful benefits compared to standard endocrine therapy, positioning this drug as a new standard of care for early-stage patients. These unprecedented data, from the second positive phase III trial, will be presented at a medical meeting and shared with global health authorities, offering renewed hope for patients.

Source: Roche, published under the title "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredes..." - 19 November 2025

Novartis Makes Major Investment in North Carolina for Innovative Pharma Hub

Novartis accelerates pharmaceutical innovation in the U.S.: a $23 billion investment for a manufacturing hub in North Carolina, creating 700 jobs by 2030 and ensuring local production of key drugs in oncology, immunology, and more, strengthening the national supply chain. This significant step reinforces Novartis's commitment to patients and the American economy.

Source: Novartis, published under the title "Novartis announces plans to build flagship manufacturing hub..." - 19 November 2025

GSK and LTZ Join Forces to Revolutionize Cancer Treatments with Myeloid Engagers

GSK and LTZ are joining forces to revolutionize oncology: Developing up to four first-class myeloid cell engagers targeting hematological and solid tumors. This innovative platform combines powerful anti-cancer efficacy with a safety profile suitable for community-based treatments, enhancing GSK's expertise in innovative technologies for transformative therapeutic advancements.

Source: Gsk, published under the title "GSK and LTZ announce strategic collaboration to advance nove..." - 19 November 2025

Lynkuet™ Approved in EU to Alleviate Menopausal and Breast Cancer Hot Flashes

Lynkuet™: The EU approves an innovative hormone-free treatment for hot flashes related to menopause or breast cancer. This dual neurokinin receptor antagonist (NK-1 and NK-3) provides significant relief, based on positive results from OASIS studies, effectively reducing the frequency and severity of symptoms. A major advancement to improve women's quality of life, with a favorable safety profile demonstrated in four clinical trials. This new non-hormonal option addresses a crucial need, supporting daily well-being against these often debilitating disorders. Bayer thus reinforces its commitment to women's health, offering a personalized and accessible option.

Source: Bayer, published under the title "Lynkuet™ (elinzanetant) approved in the EU for the treatment..." - 18 November 2025

Biotech & Genetics

Enza Zaden Adopts Fulcrum® to Accelerate Plant Breeding

The Dutch company Enza Zaden, specializing in the selection, production, and sale of professional vegetable seeds, has signed a strategic agreement with the American company Pairwise to utilize its Fulcrum® platform, a precise gene-editing technology that enhances research on plant crops. This collaboration, aimed at improving varieties, positions Enza Zaden as a leader in innovative seeds.

SEPEHR ACHARD, Source: Igronews, published under the title "Enza Zaden Licenses Pairwise’s Fulcrum® Platform to Advance ..." - 18 November 2025

HEINZ Innovates with a Gravy for Thanksgiving Leftovers

Inspired by the legendary Moist Maker from a cult 90s sitcom, HEINZ Leftover Gravy transforms traditional Thanksgiving sauce into an innovative and convenient condiment to elevate your leftover sandwiches. This squeezable bottle, rich in turkey broth flavors, targets millennials who are reinventing the holidays, making every bite nostalgic and irresistible. Available now on Walmart.com with an exclusive kit, it's the perfect ally to extend the magic of family celebrations!

Source: Kraft Heinz, published under the title "HEINZ Debuts First-Ever Gravy Condiment Exclusively for Than..." - 18 November 2025